MedTrace Logo

Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis

NCT04458688 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2022-06-06

No results posted yet for this study

Summary

The investigators intend to examine the effects of ocrelizumab use in African American multiple sclerosis disease course compared to Caucasian disease course utilizing imaging measures with magnetic resonance imaging (MRI) and optical coherence tomography angiography (OCT-A)..

Conditions

  • Multiple Sclerosis, Relapsing-Remitting

Interventions

OTHER

Observation of Ocrelizumab as Treatment in RRMS Patients

It is decided by the patient and their physician to begin taking ocrelizumab PRIOR to study enrollment. The study is only observing the effects of ocrelizumab as a pre-decided treatment option for a patient's MS.

Sponsors & Collaborators

  • Wayne State University

    lead OTHER

Principal Investigators

  • Evanthia Bernitsas, MD · Wayne State University

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-20
Primary Completion
2025-07-31
Completion
2030-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04458688 on ClinicalTrials.gov